Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?

• Main Authors: Selma Addou (Author), Clémentine Sarkozy (Author), Julien Lazarovici (Author), Stéphane Champiat (Author), Aspasia Stamatoullas (Author), Fabrice Jardin (Author), Vincent Ribrag (Author), Aurélien Marabelle (Author), Jean-Marie Michot (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Classical Hodgkin lymphoma is a neoplastic hematological disease. Standard first-line therapy, including chemotherapy and radiotherapy, is curative in >85% of early-stage patients, with a 5-year survival rate of >95%. However, approximately 15% of patients have hard-to-treat lymphoma with poor...